Amyloid aggregation of human islet amyloid polypeptide (hIAPP) is linked to insulin-producing islet cell death in type II diabetes. Previous studies have shown the amyloid inhibiting effects of zinc (Zn) and insulin that are co-present with hIAPP in islet cells, and the lipid membrane has been shown to significantly influence the aggregation kinetics. Increasing number of studies report the importance of developing small molecule inhibitors to suppress the hIAPP's toxicity.
Introduction
Human-IAPP (hIAPP: human islet amyloid polypeptide, also known as amylin) is a 37 residue peptide hormone (Fig.S1A ) that is co-secreted at a 1:100 molar ratio with insulin in response to blood glucose levels and normally contributes to satiety and the slowing of gastric emptying. [1] In type II diabetes, the increase in insulin production causes an increase in hIAPP amyloid deposits causing β cell damage. Biophysics studies have reported the aggregation of human-IAPP results in lipid membrane disruption following a two-step mechanism: fibril-independent pore formation and a fibril-dependent fragmentation of the lipid bilayer. [2] The presence of anionic lipids enhances monomeric hIAPP binding to the lipid membrane while the presence of curvature promotes aggregation. [3] Previous studies also reported that hIAPP forms toxic oligomers, which are alpha-helical. [4] [5] [6] Because of the cellular toxicity that associates with amyloid formation, it is important to develop small molecule compounds that inhibit/prevent amyloid aggregation and toxicity. [7] One of the frequently investigated amyloid inhibitors is epigallocatechin-gallate (EGCG; the major catechin present in green tea) ( Fig.S1B ), a polyphenolic compound found in green tea extract. [8] [9] [10] [11] [12] EGCG has been shown to be an effective amyloid inhibitor for a variety of amyloid-forming peptides and proteins. In addition to small molecule modulation, metal ions were shown to play a role in amyloid aggregation. In pancreatic β cells Zn is among the highest in the body and Zn deficiency is a common symptom in type II diabetes. [13] Zinc has been shown to coordinate with His-18 of hIAPP and promotes the formation of off-pathway oligomers that are incompetent to grow to form amyloid fibers.
Interestingly, Zn has a dual effect on hIAPP's amyloid aggregation properties in which low concentrations of Zn inhibit fiber formation but high concentrations promote aggregation. [14] [15] [16] Here we studied the combined effect of EGCG and Zinc on alleviating the amyloid aggregation of hIAPP and its cellular toxicity. We report that Zn enhances the ability of EGCG to inhibit amyloid formation in the presence and absence of membranes.
Because the membrane disruption induced by the amyloid aggregation of hIAPP is linked to islet cell death in type II diabetics, it is important to examine the efficiency of amyloid inhibition by small molecules in a membrane environment. By using a combination ThT based fluorescence and TEM, we show significant increase in the lag-time and reduction in the elongation rate, amorphous aggregate formation in presence of EGCG or EGCG:Zn complex. It is remarkable that EGCG:Zn complex stabilizes the helical structure of hIAPP.
Our results also show that EGCG-Zn complex also increases the cell viability by suppressing zinc's toxicity in cells.
Materials and Methods

Chemicals
Lyophilized hIAPP with amidated C-termini was purchased from Peptide Institute Inc (Osaka, Japan). In order to avoid undesired aggregation, hIAPP solution was carefully prepared according to the method published previously. [17] The concentration of hIAPP was spectroscopically determined based on a molar extinction coefficient of 1490 M -1 cm -1 at 280 nm. Two lipids in the powder form, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1-palmitoyl-2oleoyl-sn-glycero-3-phospho-rac-(1-glycerol) (POPG), were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL). ThT was obtained from Wako Pure Chemical Industries, Ltd. ZnCl2, and EGCG and the other reagents were purchased from Nacalai Tesque (Kyoto, Japan).
Preparation of lipid vesicles
Large unilamellar vesicles (LUVs) with a diameter of 100 nm were prepared as described previously. [18] Briefly, POPC and POPG lipids were first dissolved in chloroform and were mixed at a 7:3 molar ratio for mimicking a mixed anionic/zwitterionic membrane system. The solvent was removed under a steam of nitrogen and dried overnight to generate a lipid film which was next rehydrated in 20 mM HEPES (pH 7.4) containing 50 mM NaCl. Lipid suspension was subjected to 5 rounds of freeze-thaw and the resulting solution was extruded 23 times through 100-nm polycarbonate membranes (Whatman, Clifton, NJ) using a mini-extruder (Avanti Polar Lipids, Inc., Alabaster, AL). Unless otherwise noted, LUVs which consisted of 250 μM lipids were used for the current study.
ThT assay for amyloid formation of hIAPP
Kinetics of amyloid fibrillation at 37 °C were monitored using 5 μM hIAPP in 20 mM HEPES buffer (pH 7.4) containing 5 μM ThT and 50 mM NaCl in the presence and absence of LUVs. Other effectors of hIAPP amyloid generation including Zn(II), EGCG, or EGCG:Zn(II) mixture with a 1:1 molar ratio were added to hIAPP sample solution at the desired concentration.
ThT-based monitoring was performed with a sealed 96-well microplate (Greiner-Bio-One, Tokyo, Japan). ThT fluorescence intensity was observed in a microplate reader (MTP-810, Corona Electric Co. Ibaraki, Japan) every 3 min following 10-sec shaking. The excitation and emission wavelengths were set at 450 and 490 nm, respectively. Kinetic parameters of amyloid formation were obtained by the following equation; [19] 
where yi + mit and yf + mft indicate initial and final baselines, respectively. k and t indicate the rate constant of elongation and time, respectively. t0 is the half-time when ThT fluorescence reaches 50% of its maximum intensity. The lag time was calculated with the relationship, lag time = t0 -2(1/k).
Circular dichroism spectroscopy
Far-UV circular dichroism (CD) spectra were obtained at a concentration of 15 μM hIAPP dissolved in 20 mM HEPES containing 50 mM NaCl and 500 μM lipid in LUVs. Zn(II), EGCG, or EGCG:Zn(II) (1:1) complex was added to hIAPP sample solution at the desired concentration. CD measurements were performed on a Jasco J820 spectropolarimeter (Tokyo, Japan) using a quartz cuvette with a light path of 0.1 cm. A cell holder equipped with a water circulator was used to keep the sample temperature constant at 37 °C. Spectra were presented as mean residue ellipticity, [q] (deg cm 2 dmol −1 ), after subtraction of the solvent background.
Transmission electron microscopy
All transmission electron microscopy (TEM) images were obtained using a HITACHI H-7650 transmission microscope (Hitachi, Tokyo, Japan) at 20 °C with a voltage of 80 kV. Each sample solution was applied onto a collodion-coated copper grid (Nisshin EM Co., Tokyo, Japan), and negatively stained with 2% (weight/weight) ammonium molybdate as reported previously. [18] 2.6
Preparation of EGCG:Zn(II) complex
EGCG:Zn(II) complex was prepared by mixing ZnCl2 and EGCG at the desired molar ratio in 20 mM HEPES buffer (pH 7.4) containing 50 mM NaCl. The absorption spectra of EGCG:Zn(II) complex were acquired using Hitachi U-3000 spectrometer (Hitachi, Tokyo, Japan).
Cell toxicity experiments
To prepare hIAPP fibrils for the cell proliferation assays, lyophilized hIAPP monomer was solubilized in Milli-Q water which was adjusted to pH 4 with HCl. Stock solutions were prepared by adding sample buffer (50 mM NaCl, 20 mM HEPES, pH 7.4) to a final concentration of 0.1 mg/ml. Peptide solutions at 100 µM were then treated with either 1 or 5 molar equivalents of EGCG:Zn(II). Peptide solutions at 100 µM were then treated with either 1 or 5 molar equivalents of EGCG:Zn(II). To form aggregates, peptides were incubated at room temperature with shaking at 750 rpm for 24 hours. RIN-5F cells (purchased from ATCC, cat# CRL-2058, 61465080) were grown in RPMI-1640 media with 2 mM L-glutamine supplemented with 10% fetal bovine serum in a humidified incubator at 37 °C with 5% CO2. Cells were kept between passage numbers 5-15.
Cell were cultured in 10-cm cell culture dishes. For cell viability assays, 90µl of cells were dispensed to a total of 30,000 cells per well in 96 flat-bottom well trays and incubated for 24 hours at 37 °C with 5% CO2 prior the assay. Cell proliferation was measured by 3-(4,5-dimethylthiazol-2yl)-2,5-di-phenyltetrazolium bromide (MTT) assay (CellTiter 96 Non-Radioactive Cell Proliferation Assay, Promega). 10 µL of peptides (freshly dissolved and aggregated) were added to each well to a final concentration of 1, 5 or 10 µM. After 24h incubation the cell proliferation was determined as described by the manufacturer. In short, 15 µL Dye solution was added to each well. After incubation at 37 °C for 3-3.5 hours. 100 µL of solubilization solution/stop mix was added. Plates were left at room temperature for 12 hours with gentle shaking. The absorbance was measured at 570 nm and 700 nm (background). Data was corrected for the background by subtracting the absorbance at 700nm from the absorbance at 570nm. The data was normalized with cells treated with 1% (w/v) SDS to 0% reduction, and cells treated with sample buffer to 100% reduction. Five technical replicates were used for each experiment. Values reported are the average of three independent experiments and the error is the standard deviation. Ordinary one-way ANOVA tests with Tukey's multiple comparisons were performed in respect to non-treated cells (dotted line) and individual samples (solid line). ****p<0.0001, ***p<0.0002, and *p<0.05 indicate levels of significant differences.
Dynamic light scattering measurements
EGCG solutions were prepared in 20 mM HEPES buffer (pH 7.4) containing 50 mM NaCl and mixed well by gently vortex for 30 seconds. Solution mixture of EGCG and ZnCl2 were prepared at equimolar concentration and incubated for 15 minutes at 37 ºC. The size distribution of EGCG/EGCG:Zn(II) complex solutions were measured by dynamic light scattering (DLS) at 37 ºC. All DLS experiments were performed using a DynaPro NanoStar from Wyatt Technology (Santa Barbara, CA) with a 1-µL quartz cuvette and the average values over 20 independent scans were presented.
NMR experiments
One dimensional proton NMR spectra of hIAPP were recorded on a 600 MHz Bruker Avance III spectrometer equipped with a z-axis gradient cryogenic probe at 10 ºC. The freshly dissolved hIAPP monomers in 20 mM HEPES (pH 6.5) containing 50 mM NaCl, 90% H2O, and 10% 2 H2O
were titrated with either 500 µM EGCG alone or 500 µM EGCG with 500 µM ZnCl2 . The proton NMR spectra were processed using TopSpin 3.5 (Bruker BioSpin, Germany).
Results and Discussion
Effect of EGCG and Zn(II) on hIAPP aggregation in LUVs
The formation of EGCG:Zn(II) complex in solution ( Fig.S2 ) and in 7:3 molar ratio of POPC:POPG LUVs (Fig.S3 ) was first characterized by UV-vis experiments. Experimental results reveal that EGCG is capable of binding to more than one unit of Zn(II) in solution and that the formation of EGCG:Zn(II) complex even in the membrane environment, which are in agreement with results reported in a previous study. [20] DLS experiments provided information on physical phase states of EGCG and EGCG:Zn(II) (Fig. S4 ). Hydrodynamic radius (RH) of EGCG was predominantly distributed at ~7-8 nm while RH of EGCG:Zn(II) displayed ~5, ~250, and ~300-400 nm, which indicates that EGCG exists in an aggregated form while the EGCG:Zn(II) complex forms larger aggregates ( Fig. S4 ). EGCG without an appreciable lag time (Fig. 1E ). The complexation of EGCG with Zn(II) enhanced these effects in the presence of membrane ( Fig. 1E ) and also in solution (Fig.   S4 ). In fact, 5 µM of 1:1 EGCG:Zn(II) mixture is sufficient to dramatically reduce both the elongation rate and ThT intensity in presence of LUVs ( Fig.1E and F) . At 2.5 µM of 1:1 EGCG:Zn(II) mixture, amyloid formation was completely prevented in solution as indicated by the remarkably low ThT fluorescence intensity (Fig. S5C) , while a high ThT fluorescence intensity was still observed with a slow apparent elongation rate and prolonged lag time in the absence of Zn(II) (Fig. S5B ).
Since EGCG is capable of interfering with the ThT binding to amyloid fibrils as reported elsewhere, [21, 22] the ThT-based observation of the inhibition of hIAPP's amyloid fibril formation is further confirmed by taking TEM images of the samples (Fig. 2) . As shown in the TEM images, Zn(II) alone is capable of reducing the fibril density ( Fig. 2A and B) in agreement with previous studies which showed that Zn(II) coordinates with His-18 and forms off-pathway complex that does not aggregate further to form amyloid fibrils. [15] In accordance with ThT results shown in Fig.1 , Zn(II) alone cannot completely suppress the fibril formation of hIAPP. On the other hand, both EGCG and EGCG:Zn(II) are fairly efficient in fully suppressing the fibril formation by promoting the formation of amorphous aggregates of hIAPP ( Fig. 2C-F) . It is remarkable that the amount of EGCG required to completely suppress hIAPP fibril formation is dramatically reduced by the presence of Zn(II) as evidenced from experimental results shown in Figs. 1 (D-F) and S5 (B and C).
EGCG:Zn(II) complex reduces the β-sheet content of hIAPP aggregates
These ThT and TEM results were further confirmed by CD experiments (Fig. 3) . hIAPP adopted initially a α-helical structure upon interacting with LUVs, characterized by two minima at 208 and 222 nm in the CD spectrum. Incubation of the solution generated typical CD spectra of the βsheet structure which exhibits a single minimum ~220 nm, revealing the conversion of helical structures to b-rich structures. Prediction of the content of the secondary structure using algorithm of BeStSel [23] indicated that α-helical structures of hIAPP almost transformed to β structured amyloid fibrils by showing ~1-~4% of helical structures and ~30-~40% of β structures, and that the presence of Zn(II) and/or EGCG did not affect markedly the content of the secondary structure of hIAPP amyloids (Table S1 ). The combination of CD and TEM results indicate that the formation of β-sheet structured amyloid fibrils of hIAPP in solution or in lipid bilayers both in the absence and presence of Zn(II), while the extent of fibril formation is reduced by the presence of Zn(II) ( Figs. 2A,B and 3A,B ). In addition, CD and TEM results indicate the formation of amorphous bsheet aggregates in the presence of EGCG or EGCG:Zn(II) mixture as well as enhanced inhibiting capability of EGCG in the presence of Zn(II) (Figs. 2, 3 , and S5D,E).
Thermodynamic analysis of intermolecular interactions using isothermal titration calorimetry
As the inhibitory ability of EGCG in the absence and presence of Zn(II) inhibited hIAPP amyloid aggregation, we further examined intermolecular interactions using isothermal titration calorimetry (ITC) ( Figs. 4 and S7) . ITC thermograms showed exothermic binding reactions between hIAPP and either EGCG alone or EGCG:Zn(II) mixture ( Fig. 4A and B) , indicating intermolecular interactions. ITC analyses revealed that complex formation was both driven by the negative enthalpy change (DH) and the positive entropy change (DS), and reported the apparent binding stoichiometry 'n' (the number of hIAPP binding to one EGCG or EGCG:Zn(II) complex). The values of 'n' for hIAPP-EGCG and hIAPP-EGCG:Zn(II) binding systems were ~0.5 and ~0.8, respectively. The dissociation constant (Kd) of hIAPP for EGCG (~1.1 µM) is larger than that for EGCG:Zn(II) mixture (~0.7 µM) to some extent. Thus, the results may implicate that EGCG:Zn(II) complex binds to hIAPP more tightly than EGCG and more hIAPP is capable of binding to EGCG:Zn(II) complex as compared to EGCG.
One-dimensional proton NMR spectroscopy shows formation of large aggregates between hIAPP and EGCG:Zn(II) complex
A recent study reported morphologically distinct hIAPP aggregates in the presence of EGCG and suggested interactions between hIAPP and EGCG at the atomistic resolution. [12] Thus, to further characterize effects of Zn(II) on intermolecular interactions and phase states of EGCG as well as on hIAPP amyloid aggregation, we performed a series of one-dimensional proton NMR measurements (Fig. S7, left) . NMR spectra showed line broadening of amide-proton resonances of hIAPP in the presence of EGCG (Fig.S7) , which is in agreement with a recent NMR study. [12] As EGCG aggregates were detected by DLS measurements (Fig.S4 ) and photography (Fig.S7 , right panel), binding of hIAPP (ITC analyses in Fig. 4) to EGCG aggregates was ascribed to line broadending. Interestingly, EGCG in the presence of the equimolar concentration of ZnCl2 significantly reduced the intensity of amide-proton NMR peaks (Fig.S7 ). In addition, hIAPP mixed with EGCG and ZnCl2 yielded in a precipitate whereas a turbid solution containing EGCG was observed ( Fig.S7, right panel) . Therefore, severe line broadening resulted from interactions between hIAPP and large aggregates of EGCG:Zn(II) complex as ITC analyses showed these molecular interactions.
Based on these results, we suggest that aggregate forms of EGCG serve as inhibitors of amyloid generation, and reason that Zn(II) binding reinforces intermolecular interactions among EGCG and thereby generating larger EGCG aggregates than EGCG aggregates without Zn(II) as observed in DLS measurements (Fig.S4) . Indeed, other metal ions such as aluminum have also shown to enhance the antiamyloidogenic property of EGCG due to complex formation and aggregation. [12] Oligomers of 5,5,6,6-tetrachloro-1,1,3,3-tetraethylbenzimidazolylcarbocyanine iodide (JC-1), a fluorescent dye, bound to alpha-synuclein [24] and oligomers of polyphenolic compounds including EGCG and catechin exhibited higher potency to suppress amyloid fibrillation of amyloid-b and insulin than their monomeric forms. [25, 26] Collectively, aggregated forms of EGCG:Zn(II) complex are expected to be excellent in inhibiting hIAPP amyloidogenesis in a more efficient way than EGCG by using better binding ability for hIAPP in terms of the binding affinity and the number of bound molecules as revealed in ITC analyses. In addition, it is worth noting that trapping helical structures of hIAPP by EGCG or EGCG:Zn(II) complex (Fig. 3) is also an important factor to suppress amyloidogenesis.
MTT assay
Because EGCG:Zn(II) complex is the most efficient in inhibiting amyloid formation of hIAPP, we tested whether it can also counteract the toxic effect of hIAPP by promoting cell viability. We used the reduction of MTT to evaluate the toxicity of hIAPP incubated with different molar ratios of EGCG:Zn(II) (Fig. 5 ). In agreement with previous studies, [5, 27] , monomeric hIAPP (1µM freshly dissolved) exhibit more toxicity than the fibrils of hIAPP, Fig 5A. hIAPP mixed with EGCG:Zn prior cell treatment (Fig.5C ) or incubated for 24 hours (Fig 5B) showed increased cell proliferation in comparison to hIAPP monomers and fibrils alone. This increase in cell viability was statistically significant observed when comparing 10 µM hIAPP monomers or fibers alone with peptide treated with 1 or 5 equivalents of EGCG:Zn(II) (Table S2 ). However, when fresh peptide and EGCG:Zn(II) mixture were added to cells (Fig. 5B) , the positive effect of the complex was less pronounced.
Similar to treatment with EGCG only, treatment of cells with EGCG:Zn(II) caused an increase in cell proliferation ( Figure S8 and S9 ). However, treatment with only Zn(II) caused a 40% reduction in cell viability ( Figure S9 ). These results show the toxic nature of high concentrations of free Zn(II) and the ability of EGCG:Zn complex to negate it. Experiments were performed with hIAPP monomers and fibrils treated with either EGCG or Zn ( Figure S10) . A more pronounced increase in cell viability was seen with EGCG than with EGCG:Zn(II), and a more pronounced decrease the EGCG:Zn(II) mixture was found to protect cells in our system ( Figure S8 ). Taken together, the deficiency of Zn(II) in β-cell granules involving in the T2D development [30] could be supplemented in the form of EGCG:Zn(II) complex. This can increase the cell proliferation as well as deliver Zn to deficient cells via increased membrane permeability, also can inhibit hIAPP aggregation that is linked to β-cell failure, giving this complex a unique dual effect.
Conclusions
EGCG has been shown to be an efficient inhibitor of amyloid aggregation by a variety of amyloidogenic peptides and proteins, and has also been shown to remodel amyloid fibers. [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] Although many small molecules can inhibit amyloid aggregation in solution, it is important to evaluate the efficiency of such compounds in the presence of membrane which could be directly related to their ability to suppress cell toxicity. [17, 43, 44] In this study, we have successfully 
